Home » Healthcare » Non-Hodgkin Lymphoma Therapeutics Market

Non-Hodgkin Lymphoma Therapeutics Market By Type of Therapy (Chemotherapy, Radiation Therapy, Targeted Therapy, Other Types of Therapies By Cell Type (B-cell Lymphomas, T-cell Lymphoma)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Summary
Table Of Content

Key Highlights of the Report

The global non-hodgkin lymphoma therapeutics market is segmented by type of therapy, cell type, and region. Radiation therapy category is the most popular, while chemotherapy is the two primary type of therapy segment. B-cell lymphomas category accounted for a higher share of cell type, with North America leading the market growth.

The global non-hodgkin lymphoma therapeutics market has several drivers, including the increasing incidence of non-hodgkin lymphoma, the expansion of potential pipeline medications, the high rate of diagnostics, and the susceptible pediatric population are the main drivers of the worldwide non-hodgkin lymphoma market. The need for innovative ovarian cancer medications is thought to be positively influenced by the variety of therapy options and family history of the disease. COVID-19 significantly impacted the market growth. However, the market also faces significant challenges, such as the high cost of NHL medications and their significant side effects. In addition, the market’s expansion is being constrained by strict regulatory standards.

Nonetheless, the global non-hodgkin lymphoma therapeutics market offers significant growth opportunities as prevalence rises, more clinical trials are being conducted, and many more medications are being developed.

Market Overview

The global non-hodgkin lymphoma therapeutics market has witnessed steady growth in recent years and is expected to continue growing at a CAGR of 8.80% between 2023 and 2030. The market was valued at USD 8.5 billion in 2022 and is expected to reach USD 15.34 billion in 2030.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

What Are The Main Drivers Of The Global Non-Hodgkin Lymphoma Therapeutics Market?

The global non-hodgkin lymphoma therapeutics market is driven by the increasing incidence of non-hodgkin lymphoma, the expansion of potential pipeline medications, the high rate of diagnostics, and the susceptible pediatric population are the main drivers of the worldwide non-hodgkin lymphoma market. The need for innovative ovarian cancer medications is thought to be positively influenced by the variety of therapy options and family history of the disease. COVID-19 significantly impacted the market growth.

What Are The Major Challenges Faced By The Global Non-Hodgkin Lymphoma Therapeutics Market?

The global non-hodgkin lymphoma therapeutics market also faces several challenges, including the high cost of NHL medications and their significant side effects. In addition, the market’s expansion is being constrained by strict regulatory standards.

What Are The Growth Opportunities In The Global Non-Hodgkin Lymphoma Therapeutics Market?

The global non-hodgkin lymphoma therapeutics market offers significant growth opportunities as prevalence is rising, more clinical trials are being conducted, and many more medications are being developed.

Executive Summary

Overview of the Global Non-hodgkin lymphoma therapeutics Market

The global non-hodgkin lymphoma therapeutics market has been steadily growing in recent years, driven by recent approvals, the robust pipeline, the rise in the elderly population, and unique drug designations. The industry is distinguished by a broad spectrum of therapy and cell types that appeal to various consumer preferences.

Market Definition

The phrase “lymphoma therapeutics” describes a range of medical techniques and actions used to treat lymphoma, a type of cancer that affects the lymphatic system, a part of the body’s immune system. The main objectives of lymphoma treatments are to eliminate malignant cells, stop the disease from worsening, and enhance patients’ quality of life. Lymphoma can be treated in various ways, including chemotherapy, radiation therapy, targeted therapy, immunotherapy, and stem cell transplantation. The type and stage of the lymphoma, as well as other elements like the patient’s general health and medical background, will determine the best course of treatment. Therapeutics for lymphoma are designed to bring about long-term remission and improve the prognosis for lymphoma patients.

Market Insights

The global demand for non-hodgkin lymphoma therapeutics was valued at USD 8.5 Billion in 2022 and is expected to reach USD 15.34 Billion in 2030, growing at a CAGR of 8.80% between 2023 and 2030.
Radiation therapy is the leading segment by type of therapy and held over 43% share in terms of value in 2022, while the chemotherapy segment is likely to exhibit the fastest CAGR during the forecast period.
The B-cell lymphomas segment governs the global demand for non-hodgkin lymphoma therapeutics, holding a massive share of over 80% in 2022, and is expected to grow at a rapid CAGR.
North America is fueling the growth of the non-hodgkin lymphoma therapeutics industry with over one-third share in 2022, while Asia Pacific and Europe collectively account for just under 50% share in 2022. Europe held over 22% share in 2022.
The high prevalence and awareness of all types of cancer, including several blood malignancies like non-hodgkin’s lymphoma, contributed to North America’s supremacy in the global market. At the same time, the high cost of NHL medications and their significant side effects. In addition, the market’s expansion is being constrained by strict regulatory standards; the major market restraints are the main restraints.
As prevalence is rising, more clinical trials are being conducted, and many more medications are being developed, which are the major opportunities in the market.

Segmentation by Type of Therapy

Radiation therapy is the leading segment by type of therapy and held over 43% share in terms of value in 2022.
The chemotherapy segment will likely exhibit the fastest CAGR during the forecast period.

Segmentation by Cell Type

The B-cell lymphomas segment governs the demand for non-hodgkin lymphoma therapeutics in the world, holding a massive share of over 80% in 2022, and is also expected to grow at a rapid CAGR.
The T-cell lymphoma segment contributes to the rest of the demand for non-hodgkin lymphoma therapeutics.

Segmentation by Region

North America is fueling the growth of the non-hodgkin lymphoma therapeutics industry with over one-third share in 2022.
Asia Pacific and Europe collectively account for just under 50% share in 2022, with Europe holding over 22% share in the same year.
The rest of the World, including Latin America, The Middle East, and Africa, contributes the remainder to the demand for non-hodgkin lymphoma therapeutics.

The increasing demand for non-hodgkin lymphoma therapeutics can be attributed to the growing child population and the benefits offered by non-hodgkin lymphoma therapeutics. However, the market is restrained by the high cost of NHL medications and the significant side effects related to them.

The United States is one of the largest markets for non-hodgkin lymphoma therapeutics in North America, with a significant market share. Due to an increase in lymphoma prevalence, advancements in lymphoma therapeutics, including targeted therapies and immunotherapies, and an increase in the number of new product releases by important market participants in this region. For example, the U.S. FDA approved Jaypirca (pirtobrutinib) in January 2023 as the first and only non-covalent (reversible) Bruton’s tyrosine kinase (BTK) BTK inhibitor for adult patients with relapsed or refractory mantle cell lymphoma following at least two lines of systemic therapy, including a (BTK) inhibitor.

China is also a major market for non-hodgkin lymphoma therapeutics in Asia, with a significant market share, due to a growth in the number of people who have lymphoma and the number of measures being taken in the R&D sector to create cutting-edge medicines for the disease. A rise in the elderly population in developing nations like India, China, Japan, and South Korea and increased awareness of the available lymphoma treatment choices are other factors driving the market’s expansion.

Overall, the increasing demand for non-hodgkin lymphoma therapeutics can be attributed to the market growth due to increased pharmaceutical companies’ R&D spending and rising healthcare costs in industrialized nations like the United States and Canada.

While the non-hodgkin lymphoma therapeutics market is growing, it faces challenges from the high cost of NHL medications and their significant side effects. In addition, the market’s expansion is being constrained by strict regulatory standards are the major market restraints. Manufacturers are innovating and forming partnerships to stay competitive.

Non-Hodgkin Lymphomas are More Common, Which will Boost the Market.

The present trends of greater prevalence of nearly all types of cancers, including numerous types of non-hodgkin lymphomas, are the main drivers of this market for non-hodgkin lymphoma treatment. Non-Hodgkin lymphomas can vary greatly in their aggressiveness, so a precise treatment strategy is necessary. Effective and cutting-edge non-hodgkin lymphoma therapy items frequently lead to better and more favorable clinical outcomes. Many of these malignancies frequently don’t show signs until the disease progresses. At this point, strong and effective therapies are required for improved clinical results. During the projected period, these factors are anticipated to support the growth of the non-hodgkin lymphoma therapy market.

An important motivator is a desire for better clinical and therapeutic outcomes for patients with non-hodgkin lymphomas where the illness has relapsed or become refractory. A different course of treatment is frequently needed for these types of NHL, which increases the demand for highly advanced targeted medicines such as targeted therapies and immunotherapies.

Higher Adoption of Non-Hodgkin Lymphoma Treatment Products Due to High Cure Rates

One of the main driving forces is the continued and expanded R&D activity in creating effective therapies for various non-hodgkin lymphomas. Many NHLs are now being identified early thanks to the development of more sophisticated diagnostic tools, which improve patient prognosis. The market for non-hodgkin lymphoma treatments is anticipated to rise due to positive cure rates. A better prognosis for an illness increases the likelihood that people will use improved treatment, which further increases the income generated by the global market. This is since effective diagnostic methods, great cure rates, and modern therapies frequently go hand in hand for better treatment outcomes.

The Adoption of Advanced Therapeutics is Limited by the High Cost of Approved Therapeutics in Emerging Economies

Numerous blood malignancies, including lymphomas, have sharply increased prevalence rates. These trends have also been observed in several developing nations. The high prices associated with some medicines, such as immunotherapies, are the main obstacles to expanding the non-hodgkin lymphoma therapy industry. This substantially limits the number of patients receiving complex and cutting-edge treatment; most lymphoma patients go untreated. Patients frequently cannot embrace these cutting-edge treatment choices, which frequently produce better clinical outcomes, due to the lack of suitable payment plans and special considerations by the regional governments.

The worldwide NHL therapies market faces significant growth barriers due to limited access to therapy.

Limited access to treatment for most patients worldwide is one of the biggest issues facing the market. Nearly all approved medications for treating non-hodgkin lymphoma are available in most of North America and Europe. However, developing and undeveloped economies have few therapeutic alternatives for treating diseases. Despite the high occurrence of different blood malignancies, such as non-hodgkin lymphoma, in these nations, patients find it challenging to receive treatment on time due to the poor availability of treatment alternatives. Due in part to the lack of patient assistance programmes, the lack of advanced healthcare infrastructure, and the high cost of medicines, a sizeable segment of the patient population in these countries cannot afford treatment.

Non-Hodgkin lymphoma incidence rising

The American Cancer Society estimates about 80,470 new cases of non-hodgkin lymphoma per year. The age ranges between 80 and 84 for females, and 85 to 89 for males is when the highest rates are observed. Some of these tumors are incredibly aggressive. Better clinical outcomes are becoming increasingly important to properly treat patients. As a result, it stimulates market expansion.

Increased awareness of healthcare

People are becoming more health conscious, so medications are expected to help the market grow. The market is anticipated to be stimulated simultaneously by novel drug introductions to treat ovarian cancer. Many researchers are funding the development of pharmaceuticals that will benefit the market. This expands the market’s window of opportunity.

Competitive Landscape

Key Players

The global non-hodgkin lymphoma therapeutics market is highly competitive, with the presence of several key players. Some of the major players in the market and their market share are as follows:

AstraZeneca PLC
Baxter International Inc.
Bayer AG
Bristol Myers Squibb Company
Eli Lilly and Company
F. Hoffmann La-Roche Ltd
GlaxoSmithKline PLC
Seattle Genetics
Teva Pharmaceuticals
Takeda Pharmaceutical Company Limited
Spectrum Pharmaceuticals Inc.
Janssen Pharmaceuticals Inc.

These companies focus on product innovation, expanding their distribution channels, and mergers and acquisitions to stay ahead in the market. The major players in the global non-hodgkin lymphoma therapeutics market constantly strive to stay ahead by introducing new products and innovations.

An innovative gene therapy medicine called Breyanzi (lisocabtagene maraleucel) received commercial approval in the European Union in January 2022 to treat adult patients with diffuse large B-cell lymphoma.

The Food and Drug Administration (FDA) granted C-CAR039 approval in January 2022 for treating patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL). C-CAR039 is a novel autologous bi-specific CAR-T therapy targeting both CD19 and CD20 antigens, and it has been given both Regenerative Medicine Advanced Therapy (RMAT) Designation and Fast Track Designation.

According to a Bristol Myers Squibb Company, Breyanzi, a CAR-T cell therapy, has been approved by the FDA for the treatment of large B-cell lymphoma in patients who have relapsed or who have not responded to prior therapies following the two other kinds of systematic treatments.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Summary of Key Findings

This type of lymphoma therapy market is experiencing considerable demand due to the significant prevalence of numerous non-hodgkin lymphoma subtypes, recent product approvals, and promising pipeline candidates from several market participants. Driving market growth
Market segmented by type of therapy, cell type, and region.
Radiation therapy is the most popular, with chemotherapy as the primary user segment.
B-cell lymphomas are the most common cell types.
North America is leading market growth; the market is highly competitive with key players including AstraZeneca PLC, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, Seattle Genetics, Teva Pharmaceuticals, Takeda Pharmaceutical Company Limited, Spectrum Pharmaceuticals Inc., and Janssen Pharmaceuticals Inc.

Future Outlook

Positive outlook for the global non-hodgkin lymphoma therapeutics market with significant growth potential in the North American region
As prevalence is rising, more clinical trials are being conducted, and many more medications are being developed. To drive growth
Challenges from the high cost of NHL medications and their significant side effects. In addition, the market’s expansion is being constrained by strict regulatory standards are the major market restraints.
Key players to focus on product innovation, expanding market reach and maintaining competitive pricing to stay ahead in the market.

Segmentation

By Type of Therapy
- Chemotherapy
- Radiation Therapy
- Targeted Therapy
- Other Types of Therapies
By Cell Type
- B-cell Lymphomas
- T-cell Lymphoma
By Region

North America
- The US.
- Canada
- Mexico
Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Data Modelling
1.3.2.1. Company Share Analysis Model
1.3.2.2. Revenue Based Modelling
1.3.3. Phase III – Primary Research
1.3.4. Research Limitations
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Non-Hodgkin Lymphoma Therapeutics Market
2.2. Global Non-Hodgkin Lymphoma Therapeutics Market, By Type of Therapy
2.3. Global Non-Hodgkin Lymphoma Therapeutics Market, By Cell Type
2.4. Global Non-Hodgkin Lymphoma Therapeutics Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Non-Hodgkin Lymphoma Therapeutics Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Type of Therapy
3.5.2. Cell Type
3.5.3. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Type of Therapy Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Non-Hodgkin Lymphoma Therapeutics Market, By Type of Therapy
7.1. Global Non-Hodgkin Lymphoma Therapeutics Market Overview, by Type of Therapy
7.1.1. Global Non-Hodgkin Lymphoma Therapeutics Market Revenue Share, By Type of Therapy, 2022 Vs 2030 (in %)
7.2. Chemotherapy
7.2.1. Global Non-Hodgkin Lymphoma Therapeutics Market, By Region, 2017-2030 (US$ Bn)
7.3. Radiation Therapy
7.3.1. Global Non-Hodgkin Lymphoma Therapeutics Market, By Region, 2017-2030 (US$ Bn)
7.4. Targeted Therapy
7.4.1. Global Non-Hodgkin Lymphoma Therapeutics Market, By Region, 2017-2030 (US$ Bn)
7.5. Other Types of Therapies
7.5.1. Global Non-Hodgkin Lymphoma Therapeutics Market, By Region, 2017-2030 (US$ Bn)

8. Global Non-Hodgkin Lymphoma Therapeutics Market, By Cell Type
8.1. Global Non-Hodgkin Lymphoma Therapeutics Market Overview, by Cell Type
8.1.1. Global Non-Hodgkin Lymphoma Therapeutics Market, By Cell Type, 2022 vs 2030 (in %)
8.2. B-cell Lymphomas
8.2.1. Global Non-Hodgkin Lymphoma Therapeutics Market, By Region, 2017-2030 (US$ Bn)
8.3. T-cell Lymphoma
8.3.1. Global Non-Hodgkin Lymphoma Therapeutics Market, By Region, 2017-2030 (US$ Bn)

9. Global Non-Hodgkin Lymphoma Therapeutics Market, By Region
9.1. Global Non-Hodgkin Lymphoma Therapeutics Market Overview, by Region
9.1.1. Global Non-Hodgkin Lymphoma Therapeutics Market, By Region, 2022 vs 2030 (in%)
9.2. Type of Therapy
9.2.1. Global Non-Hodgkin Lymphoma Therapeutics Market, By Type of Therapy, 2017-2030 (US$ Bn)
9.3. Cell Type
9.3.1. Global Non-Hodgkin Lymphoma Therapeutics Market, By Cell Type, 2017-2030 (US$ Bn)

10. North America Non-Hodgkin Lymphoma Therapeutics Market Analysis
10.1. North America Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2030(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. North America Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2030(US$ Bn)
10.2.1. Overview
10.2.2. SRC Analysis
10.3. North America Non-Hodgkin Lymphoma Therapeutics Market, by Country, 2017-2030 (US$ Bn)
10.3.1. North America Non-Hodgkin Lymphoma Therapeutics Market, by Country, 2022 Vs 2030 (in%)
10.3.2. U.S.
10.3.2.1. U.S. Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.2.2. U.S. Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
10.3.2.3. U.S. Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
10.3.3. Canada
10.3.3.1. Canada Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.3.2. Canada Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
10.3.3.3. Canada Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
10.3.4. Mexico
10.3.4.1. Mexico Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.3.4.2. Mexico Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
10.3.4.3. Mexico Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)

11. Europe Non-Hodgkin Lymphoma Therapeutics Market Analysis
11.1. Europe Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2030(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Europe Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2030(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Europe Non-Hodgkin Lymphoma Therapeutics Market, by Country, 2017-2030 (US$ Bn)
11.3.1. Europe Non-Hodgkin Lymphoma Therapeutics Market, by Country, 2022 Vs 2030 (in%)
11.3.2. Germany
11.3.2.1. Germany Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.2.2. Germany Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
11.3.2.3. Germany Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
11.3.3. France
11.3.3.1. France Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.3.2. France Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
11.3.3.3. France Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
11.3.4. UK
11.3.4.1. UK Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.4.2. UK Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
11.3.4.3. UK Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
11.3.5. Italy
11.3.5.1. Italy Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.5.2. Italy Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
11.3.5.3. Italy Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
11.3.6. Spain
11.3.6.1. Spain Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.6.2. Spain Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
11.3.6.3. Spain Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
11.3.7. Rest of Europe
11.3.7.1. Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.3.7.2. Rest of Europe Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
11.3.7.3. Rest of Europe Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)

12. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Analysis
12.1. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2030(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2030(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market, by Country, 2017-2030 (US$ Bn)
12.3.1. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market, by Country, 2022 Vs 2030 (in%)
12.3.2. China
12.3.2.1. China Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.2.2. China Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
12.3.2.3. China Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
12.3.3. Japan
12.3.3.1. Japan Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.3.2. Japan Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
12.3.3.3. Japan Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
12.3.4. India
12.3.4.1. India Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.4.2. India Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
12.3.4.3. India Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
12.3.5. South Korea
12.3.5.1. South Korea Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.5.2. South Korea Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
12.3.5.3. South Korea Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
12.3.6. South-East Asia
12.3.6.1. South-East Asia Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.6.2. South-East Asia Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
12.3.6.3. South-East Asia Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
12.3.7. Rest of Asia Pacific
12.3.7.1. Rest of Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.3.7.2. Rest of Asia Pacific Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
12.3.7.3. Rest of Asia Pacific Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)

13. Latin America Non-Hodgkin Lymphoma Therapeutics Market Analysis
13.1. Latin America Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2030(US$ Bn)
13.1.1. Overview
13.1.2. SRC Analysis
13.2. Latin America Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2030(US$ Bn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. Latin America Non-Hodgkin Lymphoma Therapeutics Market, by Country, 2017-2030 (US$ Bn)
13.3.1. Latin America Non-Hodgkin Lymphoma Therapeutics Market, by Country, 2022 Vs 2030 (in%)
13.3.2. Brazil
13.3.2.1. Brazil Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.2.2. Brazil Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
13.3.2.3. Brazil Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
13.3.3. Argentina
13.3.3.1. Argentina Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.3.2. Argentina Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
13.3.3.3. Argentina Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
13.3.4. Rest of Latin America
13.3.4.1. Rest of Latin America Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.3.4.2. Rest of Latin America Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
13.3.4.3. Rest of Latin America Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)

14. Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market Analysis
14.1. Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2030(US$ Bn)
14.1.1. Overview
14.1.2. SRC Analysis
14.2. Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2030(US$ Bn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market, by Country, 2017-2030 (US$ Bn)
14.3.1. Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market, by Country, 2022 Vs 2030 (in%)
14.3.2. GCC Countries
14.3.2.1. GCC Countries Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.2.2. GCC Countries Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
14.3.2.3. GCC Countries Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
14.3.3. South Africa
14.3.3.1. South Africa Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.3.2. South Africa Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
14.3.3.3. South Africa Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)
14.3.4. Rest of Middle East and Africa
14.3.4.1. Rest of Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.3.4.2. Rest of Middle East and Africa Non-Hodgkin Lymphoma Therapeutics, By Type of Therapy, 2017-2030 (US$ Bn)
14.3.4.3. Rest of Middle East and Africa Non-Hodgkin Lymphoma Therapeutics, By Cell Type, 2017-2030 (US$ Bn)

15. Company Profiles
15.1. AstraZeneca PLC
15.1.1. Company Overview
15.1.2. Products/Services Portfolio
15.1.3. Geographical Presence
15.1.4. Financial Summary
15.1.4.1. Market Revenue and Net Profit (2019-2022)
15.1.4.2. Business Segment Revenue Analysis
15.1.4.3. Geographical Revenue Analysis
15.2. Baxter International Inc.
15.3. Bayer AG
15.4. Bristol Myers Squibb Company
15.5. Eli Lilly and Company
15.6. F. Hoffmann La-Roche Ltd
15.7. GlaxoSmithKline PLC
15.8. Seattle Genetics
15.9. Teva Pharmaceuticals
15.10. Takeda Pharmaceutical Company Limited
15.11. Spectrum Pharmaceuticals Inc.
15.12. Janssen Pharmaceuticals Inc.

List of Figures
FIG. 1 Global Non-Hodgkin Lymphoma Therapeutics Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Non-Hodgkin Lymphoma Therapeutics Market Segmentation
FIG. 4 Global Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2022 (US$ Bn)
FIG. 5 Global Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2022 (US$ Bn)
FIG. 6 Global Non-Hodgkin Lymphoma Therapeutics Market, by Geography, 2022 (US$ Bn)
FIG. 7 Attractive Investment Proposition, by Type of Therapy, 2022
FIG. 8 Attractive Investment Proposition, by Cell Type, 2022
FIG. 9 Attractive Investment Proposition, by Geography, 2022
FIG. 10 Global Market Share Analysis of Key Non-Hodgkin Lymphoma Therapeutics Market Manufacturers, 2022
FIG. 11 Global Market Positioning of Key Non-Hodgkin Lymphoma Therapeutics Market Manufacturers, 2022
FIG. 12 Global Non-Hodgkin Lymphoma Therapeutics Market Value Contribution, By Type of Therapy, 2022 & 2030 (Value %)
FIG. 13 Global Non-Hodgkin Lymphoma Therapeutics Market, by Chemotherapy, Value, 2017-2030 (US$ Bn)
FIG. 14 Global Non-Hodgkin Lymphoma Therapeutics Market, by Radiation Therapy, Value, 2017-2030 (US$ Bn)
FIG. 15 Global Non-Hodgkin Lymphoma Therapeutics Market, by Targeted Therapy, Value, 2017-2030 (US$ Bn)
FIG. 16 Global Non-Hodgkin Lymphoma Therapeutics Market, by Other Types of Therapies, Value, 2017-2030 (US$ Bn)
FIG. 17 Global Non-Hodgkin Lymphoma Therapeutics Market Value Contribution, By Cell Type, 2022 & 2030 (Value %)
FIG. 18 Global Non-Hodgkin Lymphoma Therapeutics Market, by B-cell Lymphomas, Value, 2017-2030 (US$ Bn)
FIG. 19 Global Non-Hodgkin Lymphoma Therapeutics Market, by T-cell Lymphoma, 2017-2030 (US$ Bn)
FIG. 20 North America Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 21 U.S. Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 22 Canada Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 23 Europe Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 24 Germany Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 25 France Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 26 U.K. Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 27 Italy Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 28 Spain Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 29 Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 30 Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 31 China Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 32 Japan Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 33 India Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 34 South Korea Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 35 South-East Asia Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 36 Rest of Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 37 Latin America Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 38 Brazil Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 39 Mexico Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 40 Rest of Latin America Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 41 Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 42 GCC Countries Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 43 South Africa Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)
FIG. 44 Rest of Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market, 2017-2030 (US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Non-Hodgkin Lymphoma Therapeutics Market
TABLE 2 Global Non-Hodgkin Lymphoma Therapeutics Market: Market Drivers Impact Analysis
TABLE 3 Global Non-Hodgkin Lymphoma Therapeutics Market: Market Restraints Impact Analysis
TABLE 4 Global Non-Hodgkin Lymphoma Therapeutics Market, by Competitive Benchmarking, 2022
TABLE 5 Global Non-Hodgkin Lymphoma Therapeutics Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Non-Hodgkin Lymphoma Therapeutics Market, by Key Strategies Analysis, 2022
TABLE 7 Global Non-Hodgkin Lymphoma Therapeutics Market, by Chemotherapy, By Region, 2017-2022 (US$ Bn)
TABLE 8 Global Non-Hodgkin Lymphoma Therapeutics Market, by Chemotherapy, By Region, 2023-2030 (US$ Bn)
TABLE 9 Global Non-Hodgkin Lymphoma Therapeutics Market, by Radiation Therapy, By Region, 2017-2022 (US$ Bn)
TABLE 10 Global Non-Hodgkin Lymphoma Therapeutics Market, by Radiation Therapy, By Region, 2023-2030 (US$ Bn)
TABLE 11 Global Non-Hodgkin Lymphoma Therapeutics Market, by Targeted Therapy, By Region, 2017-2022 (US$ Bn)
TABLE 12 Global Non-Hodgkin Lymphoma Therapeutics Market, by Targeted Therapy, By Region, 2023-2030 (US$ Bn)
TABLE 13 Global Non-Hodgkin Lymphoma Therapeutics Market, by Other Types of Therapies, By Region, 2017-2022 (US$ Bn)
TABLE 14 Global Non-Hodgkin Lymphoma Therapeutics Market, by Other Types of Therapies, By Region, 2023-2030 (US$ Bn)
TABLE 15 Global Non-Hodgkin Lymphoma Therapeutics Market, by B-cell Lymphomas, By Region, 2017-2022 (US$ Bn)
TABLE 16 Global Non-Hodgkin Lymphoma Therapeutics Market, by B-cell Lymphomas, By Region, 2023-2030 (US$ Bn)
TABLE 17 Global Non-Hodgkin Lymphoma Therapeutics Market, by T-cell Lymphoma, By Region, 2017-2022 (US$ Bn)
TABLE 18 Global Non-Hodgkin Lymphoma Therapeutics Market, by T-cell Lymphoma, By Region, 2023-2030 (US$ Bn)
TABLE 19 Global Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 20 Global Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 21 Global Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 22 Global Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 23 Global Non-Hodgkin Lymphoma Therapeutics Market, by Region, 2017-2022 (US$ Bn)
TABLE 24 Global Non-Hodgkin Lymphoma Therapeutics Market, by Region, 2023-2030 (US$ Bn)
TABLE 25 North America Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 26 North America Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 27 North America Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 28 North America Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 29 North America Non-Hodgkin Lymphoma Therapeutics Market, by Country, 2017-2022 (US$ Bn)
TABLE 30 North America Non-Hodgkin Lymphoma Therapeutics Market, by Country, 2023-2030 (US$ Bn)
TABLE 31 United States Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 32 United States Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 33 United States Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 34 United States Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 35 Canada Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 36 Canada Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 37 Canada Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 38 Canada Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 39 Mexico Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 40 Mexico Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 41 Mexico Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 42 Mexico Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 43 Europe Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 44 Europe Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 45 Europe Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 46 Europe Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 47 Europe Non-Hodgkin Lymphoma Therapeutics Market, by Country, 2017-2022 (US$ Bn)
TABLE 48 Europe Non-Hodgkin Lymphoma Therapeutics Market, by Country, 2023-2030 (US$ Bn)
TABLE 49 Germany Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 50 Germany Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 51 Germany Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 52 Germany Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 53 France Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 54 France Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 55 France Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 56 France Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 57 United Kingdom Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 58 United Kingdom Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 59 United Kingdom Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 60 United Kingdom Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 61 Italy Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 62 Italy Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 63 Italy Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 64 Italy Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 65 Spain Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 66 Spain Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 67 Spain Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 68 Spain Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 69 Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 70 Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 71 Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 72 Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 73 Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 74 Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 75 Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 76 Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 77 China Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 78 China Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 79 China Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 80 China Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 81 Japan Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 82 Japan Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 83 Japan Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 84 Japan Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 85 India Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 86 India Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 87 India Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 88 India Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 89 South Korea Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 90 South Korea Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 91 South Korea Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 92 South Korea Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 93 South-East Asia Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 94 South-East Asia Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 95 South-East Asia Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 96 South-East Asia Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 97 Rest of Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 98 Rest of Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 99 Rest of Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 100 Rest of Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 101 Latin America Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 102 Latin America Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 103 Latin America Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 104 Latin America Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 105 Brazil Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 106 Brazil Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 107 Brazil Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 108 Brazil Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 109 Argentina Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 110 Argentina Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 111 Argentina Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 112 Argentina Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 113 Rest of Latin America Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 114 Rest of Latin America Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 115 Rest of Latin America Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 116 Rest of Latin America Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 117 Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 118 Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 119 Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 120 Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 121 GCC Countries Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 122 GCC Countries Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 123 GCC Countries Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 124 GCC Countries Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 125 South Africa Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 126 South Africa Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 127 South Africa Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 128 South Africa Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)
TABLE 129 Rest of Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2017-2022 (US$ Bn)
TABLE 130 Rest of Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market, by Type of Therapy, 2023-2030 (US$ Bn)
TABLE 131 Rest of Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2017-2022 (US$ Bn)
TABLE 132 Rest of Middle East and Africa Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2023-2030 (US$ Bn)

Frequently Asked Questions

What is the current size of the global non-hodgkin lymphoma therapeutics market?

The global non-hodgkin lymphoma therapeutics market was valued at USD 8.5 Billion in 2022.

What is the expected growth rate of the non-hodgkin lymphoma therapeutics market between 2023 and 2030?

The non-hodgkin lymphoma therapeutics market is expected to grow at a CAGR of 8.80% between 2023 and 2030, reaching USD 15.34 Billion in 2030.

Which segment is leading the market share in terms of type of therapy?

Radiation therapy is the leading segment by type of therapy, holding over 43% share in terms of value in 2022.

Which cell type segment governs the demand for non-hodgkin lymphoma therapeutics worldwide?

The B-cell lymphomas segment governs the demand for non-hodgkin lymphoma therapeutics in the world, holding a massive share of over 80% in 2022.

Which region is fueling the growth of the non-hodgkin lymphoma therapeutics industry?

North America is fueling the growth of the non-hodgkin lymphoma therapeutics industry, with an over one-third share in 2022.

Who are the major players in the global non-hodgkin lymphoma therapeutics market?

The top players include AstraZeneca PLC, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann La-Roche Ltd, GlaxoSmithKline PLC, Seattle Genetics, Teva Pharmaceuticals, Takeda Pharmaceutical Company Limited, Spectrum Pharmaceuticals Inc., and Janssen Pharmaceuticals Inc.

What are the major market drivers of the non-hodgkin lymphoma therapeutics industry?

Lymphoma therapy market is experiencing considerable demand due to the significant prevalence of numerous non-hodgkin lymphoma subtypes; recent product approvals and promising pipeline candidates from several market participants are the major market drivers.

What are the major market restraints of the non-hodgkin lymphoma therapeutics industry?

The high cost of NHL medications and their significant side effects. In addition, the market’s expansion is being constrained by strict regulatory standards are the major market restraints.

What are the major market opportunities of the non-hodgkin lymphoma therapeutics industry?

As prevalence is rising, more clinical trials are being conducted, and many more medications are being developed, which are the major opportunities in the non-hodgkin lymphoma therapeutics industry.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –